Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 17, 2026. The filing details material definitive agreements entered into on June 17, 2026, and equity exchange transactions occurring between June 9 and June 18, 2026, involving the company and its lender, Streeterville Capital, LLC.
Key Financial Metrics and Obligations
The filing does not provide revenue, profit, cash flow, or margin data. It focuses on the restructuring of debt and royalty obligations:
- Royalty Payments: Amendments to the Uptown 2020 and Streeterville 2022 Royalty Interests (original principal $12 million each) establish a minimum monthly royalty payment of $750,000 starting October 1, 2026.
- Debt Maturity: The maturity date of the 2021 Secured Promissory Note (original principal $6,220,812.50) was extended from July 1, 2026, to October 1, 2026.
- Equity Issuance: The company issued a total of 110,249 shares of Common Stock in exchange for 10.88 shares of Series Q Perpetual Preferred Stock held by Streeterville.
Material Changes Versus Prior Period
The primary material changes involve the extension of payment obligations and the conversion of preferred equity:
- Payment Deferral: Monthly royalty payments under the Streeterville 2022 agreement were deferred from July 1, 2026, to October 1, 2026.
- Debt Extension: The 2021 Note maturity was extended by three months to October 1, 2026.
- Capital Structure: The exchange transactions resulted in the issuance of more than 5% of the company's issued and outstanding Common Stock as of the last reported 10-Q (May 20, 2026).
Outlook, Risks, and Unusual Items
The filing indicates a strategic focus on liquidity management through debt restructuring and equity-for-debt exchanges. Key points include:
- Liquidity Management: The company has secured a three-month extension on significant royalty and debt obligations, pushing the start of increased cash outflows to October 1, 2026.
- Dilution Risk: The exchange of Series Q Preferred Stock for Common Stock resulted in significant dilution, exceeding 5% of the outstanding share count.
- Contingencies: The new royalty structure mandates a floor payment of $750,000 per month, regardless of actual royalty generation, increasing fixed cash obligations.
Investor Verification Checklist
- Verify the exact number of outstanding Common Stock shares post-exchange to confirm the dilution percentage.
- Review the full text of the Global Amendments (Exhibits 4.1 and 4.2) for any additional covenants or default triggers associated with the $750,000 monthly floor.
- Confirm the company's current cash position to assess its ability to meet the $750,000 monthly royalty obligation starting October 1, 2026.
- Check subsequent filings for any further amendments to the 2021 Note or additional equity issuances.